drugset / Trial / NCT02218684

Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects

NCT02218684

Phase 1 Completed 27 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The trial objectives were to investigate the tolerability and pharmacokinetics of 80 mg telmisartan and 2, 4 or 6 mg lacidipine administered concurrently.

Timeline

Start
1998-09
Primary completion
1998-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacidipine Small molecule 2 mg
Subject Lacidipine Small molecule 4 mg
Subject Lacidipine Small molecule 6 mg
Subject Telmisartan Other / unclassified 80 mg

Indications

No indication recorded.